Transcutaneous Auricular Vagus Nerve Stimulation in Perimenopause
Transcutaneous Auricular Vagus Nerve Stimulation in Perimenopause: EEG Signatures of Symptom Modulation
The study will test an ear-based nerve stimulation (taVNS) to see if it can ease common perimenopause symptoms like hot flashes, poor sleep, mood changes, and "brain fog". Along the way, brain activity (EEG) and heart rhythm patterns (HRV) will be tracked to find simple, reliable signs of improvement.
Because women with both mild and more severe symptoms early in the transition are included, the results can learn who benefits most and why. If successful, this study will set the stage for larger trials and could make taVNS a low-risk, affordable option to support women's brain and overall health during perimenopause.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Perimenopausal women aged 35-60 with climacteric symptoms for >6 months, irregular menstruation, and at least one menses in the past 6 months.
- Women on menopausal hormone therapy (HRT).
- Ability to understand procedures and provide informed consent.
- Willingness to complete study visits, questionnaires, EEG/HRV recordings, taVNS sessions.
- Negative urine pregnancy test.
- Access to stable internet for remote sessions or willingness to use study-provided equipment.
Exclusion criteria:
- Pregnancy, breastfeeding, or planning pregnancy during the active study period (for randomized subjects).
- Postmenopausal status.
- History of implanted stimulator.
- Clinically significant unstable cardiac disease.
- History of seizure disorder or serious neurological condition that interferes with study procedures or EEG interpretation.
- Current ear infection.
- Active severe psychiatric instability.
- Recent initiation or major dose change of hormone therapy, psychotropics, beta-blockers, anticholinergics, or other medications likely to substantially affect autonomic or symptom outcomes.
- Current participation in another interventional trial that could confound outcomes.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Active Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)
|
Transcutaneous auricular vagus nerve stimulation (taVNS) is a non-invasive neuromodulation technique that delivers mild electrical stimulation to the external ear at regions innervated by the auricular branch of the vagus nerve. |
|
Placebo Comparator: Sham Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)
|
tAVNS device with electrode placed at the external ear at regions with no active current. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Electroencephalography (EEG)
Time Frame: Baseline (Visit 2, pre-intervention) and Post Intervention (Visit 13, around 2 weeks from V2)
|
Resting Electroencephalography (EEG) will be recorded using a 64-channel system (resting alpha/theta power) |
Baseline (Visit 2, pre-intervention) and Post Intervention (Visit 13, around 2 weeks from V2)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 2026P001468
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.